OR WAIT null SECS
© 2022 MJH Life Sciences and Consultant Live. All rights reserved.
The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.
March 29, 2022
In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.
March 16, 2022
Apixaban prescription beyond 90 days showed no difference in hospitalization risk for major bleeding.
February 01, 2022
Investigators noted that clinically relevant risks could not be excluded with certainty despite not seeing a statistically significant increase in corresponding risks for more rare and severe thrombotic outcomes.
January 11, 2022
A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.
December 20, 2021
The oral suspension for rivaroxaban prevents blood clots in patients aged ≥2 years with congenital heart disease following the Fontan procedure.
December 01, 2021
Recurrent VTE shows a higher rate than expected for patients with subsegmental pulmonary embolism without proximal deep vein thrombosis managed without anticoagulation.
November 28, 2021
Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge.
November 01, 2021
Incidence rates of post-Ad26.COV2.S vaccination cerebral venous sinus thrombosis was 8.65 per 100,000 person-years.
September 27, 2021
Analysis data show 3 times more risk of intensive care unit care in patients with venous thromboembolism compared to non-VTE patients (RR: 2.78).
July 20, 2021
Data show postoperative initiation of factor XI inhibition was effective method for reducing the risk of VTE following total knee arthroplasty.